Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Dyclonine is a topical anesthetic that also has antimicrobial, anticancer, and neuroprotective properties.1,2,3 It is active against S. aureus, B. subtilis, E. coli, P. vulgaris, P. aeruginosa, C. albicans, M. lanosum, and T. mentagrophytes with minimum microbicidal concentrations (MMCs) ranging from 0.006 to 0.8% v/v.1 Dyclonine (25-100 μM) reduces aldehyde dehydrogenase (ALDH) activity in and viability of HSC-4 oral squamous cell carcinoma cells and enhances HSC-4 and OSC19 cell death induced by sulfasalazine (Item No. 15025).2 In vivo, dyclonine (5 mg/kg per day) reduces tumor volume in an HSC-2 mouse xenograft model when administered alone or in combination with sulfasalazine. Dyclonine also induces cerebral frataxin (FXN) production and decreases time to cross and the number of foot slips in a level beam test in a mouse model of Friedreich's ataxia.3
WARNING This product is not for human or veterinary use.
1. Antimicrobial properties of dyclonine hydrochloride, a new topical anesthetic. J. Am. Pharm. Assoc. 45(5), 320-325 (1956).
2. Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-
3. Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich’s ataxia. Hum. Mol. Genet. 23(25), 6848-6862 (2014).